Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
accepted:
07
10
2020
pubmed:
2
12
2020
medline:
7
4
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
The human gut microbiome has emerged as a major player in human health and disease. The liver, as the first organ to encounter microbial products that cross the gut epithelial barrier, is affected by the gut microbiome in many ways. Thus, the gut microbiome might play a major part in the development of liver diseases. The common end stage of liver disease is decompensated cirrhosis and the further development towards acute-on-chronic liver failure (ACLF). These conditions have high short-term mortality. There is evidence that translocation of components of the gut microbiota, facilitated by different pathogenic mechanisms such as increased gut epithelial permeability and portal hypertension, is an important driver of decompensation by induction of systemic inflammation, and thereby also ACLF. Elucidating the role of the gut microbiome in the aetiology of decompensated cirrhosis and ACLF deserves further investigation and improvement; and might be the basis for development of diagnostic and therapeutic strategies. In this Review, we focus on the possible pathogenic, diagnostic and therapeutic role of the gut microbiome in decompensation of cirrhosis and progression to ACLF.
Identifiants
pubmed: 33257833
doi: 10.1038/s41575-020-00376-3
pii: 10.1038/s41575-020-00376-3
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-180Références
Sender, R., Fuchs, S. & Milo, R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cell humans. Cell 164, 337–340 (2016).
pubmed: 26824647
Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).
pubmed: 27541692
pmcid: 4991899
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
pubmed: 20203603
pmcid: 3779803
Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834–841 (2014).
pubmed: 24997786
Almeida, A. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-0603-3 (2020).
doi: 10.1038/s41587-020-0603-3
pubmed: 32690973
pmcid: 7801254
Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).
pubmed: 27974040
Ridlon, J. M., Kang, D. J., Hylemon, P. B. & Bajaj, J. S. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig. Dis. 33, 338–345 (2015).
pubmed: 26045267
pmcid: 4470395
Tilg, H., Cani, P. D. & Mayer, E. A. Gut microbiome and liver diseases. Gut 65, 2035–2044 (2016).
pubmed: 27802157
Tripathi, A. et al. The gut–liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15, 397–411 (2018).
pubmed: 29748586
pmcid: 6319369
Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411 (2017).
pubmed: 28487545
Parola, M. & Pinzani, M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37–55 (2019).
pubmed: 30213667
Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749–1761 (2014).
pubmed: 24480518
Vlahcevic, Z. R., Buhac, I., Bell, C. C. Jr & Swell, L. Abnormal metabolism of secondary bile acids in patients with cirrhosis. Gut 11, 420–422 (1970).
pubmed: 5428044
pmcid: 1411544
Acharya, C., Sahingur, S. E. & Bajaj, J. S. Microbiota, cirrhosis, and the emerging oral–gut–liver axis. JCI Insight 2, e94416 (2017).
pmcid: 5841881
Bosch, J. & Garcia-Pagan, J. C. Complications of cirrhosis. I. Portal hypertension. J. Hepatol. 32, 141–156 (2000).
pubmed: 10728801
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69, 406–460 (2018).
Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59–64 (2014).
pubmed: 25079328
Claria, J. et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 64, 1249–1264 (2016).
pubmed: 27483394
Trebicka, J. et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis. Front. Immunol. 10, 476 (2019).
pubmed: 30941129
pmcid: 6434999
Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426–1437 (2013).
pubmed: 23474284
Fernandez, J. et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 67, 1870–1880 (2018).
pubmed: 28847867
Bajaj, J. S. et al. Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute on chronic liver failure and death in patients with cirrhosis. Gastroenterology https://doi.org/10.1053/j.gastro.2020.07.019 (2020).
doi: 10.1053/j.gastro.2020.07.019
pubmed: 33253686
Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 235–246 (2019).
pubmed: 30643227
Byass, P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 12, 159 (2014).
pubmed: 25286285
pmcid: 4168048
Gines, P. et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol. Hepatol. 1, 256–260 (2016).
pubmed: 28404098
Collaborators, G. B. D. C. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 245–266 (2020).
Stein, E. et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J. Hepatol. 65, 998–1005 (2016).
pubmed: 27392424
Kim, D. et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology 155, 1154–1163.e3 (2018).
pubmed: 30009816
pmcid: 6467699
Singh, S. P., Panigrahi, S., Mishra, D. & Khatua, C. R. Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia. J. Hepatol. 70, 1031–1032 (2019).
pubmed: 30782425
Allen, A. M. & Kim, W. R. Epidemiology and healthcare burden of acute-on-chronic liver failure. Semin. Liver Dis. 36, 123–126 (2016).
pubmed: 27172353
Zutshi, Y. Liver Disease Treatments: The Global Market (BCC, 2015).
Ge, P. S. & Runyon, B. A. Treatment of patients with cirrhosis. N. Engl. J. Med. 375, 767–777 (2016).
pubmed: 27557303
Arroyo, V., Moreau, R. & Jalan, R. Acute-on-chronic liver failure. N. Engl. J. Med. 382, 2137–2145 (2020).
pubmed: 32459924
Arroyo, V. et al. Acute-on-chronic liver failure in cirrhosis. Nat. Rev. Dis. Primers 2, 16041 (2016).
pubmed: 27277335
Trebicka, J. et al. The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology. J. Hepatol. 73, 842–854 (2020).
pubmed: 32673741
Sarin, S. K. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol. Int. 8, 453–471 (2014).
pubmed: 26202751
Bajaj, J. S. et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 60, 250–256 (2014).
pubmed: 24677131
pmcid: 4077926
O’Leary, J. G. et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 67, 2367–2374 (2018).
pubmed: 29315693
Hernaez, R., Sola, E., Moreau, R. & Gines, P. Acute-on-chronic liver failure: an update. Gut 66, 541–553 (2017).
pubmed: 28053053
pmcid: 5534763
Kim, T. Y. et al. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition. PLoS ONE 11, e0146745 (2016).
pubmed: 26789409
pmcid: 4720429
Li, H. et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci. Rep. 6, 25487 (2016).
pubmed: 27146801
pmcid: 4857102
Garcia-Tsao, G., Albillos, A., Barden, G. E. & West, A. B. Bacterial translocation in acute and chronic portal hypertension. Hepatology 17, 1081–1085 (1993).
pubmed: 8514258
Oh, T. G. et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 32, 878–888.e6 (2020).
pubmed: 32610095
Korpela, K. et al. Selective maternal seeding and environment shape the human gut microbiome. Genome Res. 28, 561–568 (2018).
pubmed: 29496731
pmcid: 5880245
Acharya, C. & Bajaj, J. S. Gut microbiota and complications of liver disease. Gastroenterol. Clin. North Am. 46, 155–169 (2017).
pubmed: 28164848
pmcid: 5300079
Davis, B. C. & Bajaj, J. S. The human gut microbiome in liver diseases. Semin. Liver Dis. 37, 128–140 (2017).
pubmed: 28564721
Albillos, A., Gottardi, A. & Rescigno, M. The gut–liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol. 72, 558–577 (2020).
pubmed: 31622696
Hartmann, P. et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 58, 108–119 (2013).
pubmed: 23408358
pmcid: 3695050
Henriksen, J. H., Moller, S., Ring-Larsen, H. & Christensen, N. J. The sympathetic nervous system in liver disease. J. Hepatol. 29, 328–341 (1998).
pubmed: 9722218
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut–liver axis in liver disease. J. Hepatol. 67, 1084–1103 (2017).
pubmed: 28526488
Teltschik, Z. et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology 55, 1154–1163 (2012).
pubmed: 22095436
Wang, L. et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe 19, 227–239 (2016).
pubmed: 26867181
pmcid: 4786170
Du Plessis, J. et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J. Hepatol. 58, 1125–1132 (2013).
pubmed: 23402745
Munoz, L. et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis. Hepatology 70, 925–938 (2019).
pubmed: 30414342
Trebicka, J. et al. Soluble TNF-α-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS ONE 8, e83341 (2013).
pubmed: 24386183
pmcid: 3873322
Queck, A. et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut 69, 1535–1536 (2020).
pubmed: 31270166
pmcid: 7398461
Schierwagen, R. et al. Circulating microbiome in blood of different circulatory compartments. Gut 68, 578–580 (2019).
pubmed: 29581241
Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940–947 (2014).
pubmed: 24374295
Zhang, Y. et al. Characterization of the circulating microbiome in acute-on-chronic liver failure associated with hepatitis B. Liver Int. 39, 1207–1216 (2019).
pubmed: 30864226
Villa, E. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143, 1253–1260 (2012).
pubmed: 22819864
Nery, F. et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 61, 660–667 (2015).
pubmed: 25284616
Garcia-Tsao, G., Lee, F. Y., Barden, G. E., Cartun, R. & West, A. B. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 108, 1835–1841 (1995).
pubmed: 7768390
Macdonald, S. et al. Cell death markers in patients with cirrhosis and acute decompensation. Hepatology 67, 989–1002 (2018).
pubmed: 29023872
Praktiknjo, M. et al. Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatol. Commun. 2, 211–222 (2018).
pubmed: 29404528
pmcid: 5796334
Shi, Y. et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 62, 232–242 (2015).
pubmed: 25800029
Sarin, S. K. & Choudhury, A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 13, 131–149 (2016).
pubmed: 26837712
Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell 140, 771–776 (2010).
pubmed: 20303867
Moreau, R. et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J. Hepatol. 72, 688–701 (2020).
pubmed: 31778751
Lehmann, J. M. et al. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int. 38, 875–884 (2018).
pubmed: 29105936
Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505–511 (2019).
pubmed: 31723265
pmcid: 6872939
Llopis, M. et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65, 830–839 (2016).
pubmed: 26642859
Puri, P. et al. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology 67, 1284–1302 (2018).
pubmed: 29083504
pmcid: 5867221
Jansen, C. et al. Left ventricular longitudinal contractility predicts acute-on-chronic liver failure development and mortality after transjugular intrahepatic portosystemic shunt. Hepatol. Commun. 3, 340–347 (2019).
pubmed: 30984902
pmcid: 6444053
Trebicka, J. Emergency TIPS in a Child–Pugh B patient: when does the window of opportunity open and close? J. Hepatol. 66, 442–450 (2017).
pubmed: 27984174
Trebicka, J. Predisposing factors in acute-on-chronic liver failure. Semin. Liver Dis. 36, 167–173 (2016).
pubmed: 27172359
Jansen, C. et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology 67, 1472–1484 (2018).
pubmed: 29059466
D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).
pubmed: 16298014
Jalan, R. et al. Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients. J. Hepatol. 54, 265–271 (2011).
pubmed: 21067839
Bala, S., Marcos, M., Gattu, A., Catalano, D. & Szabo, G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS ONE 9, e96864 (2014).
pubmed: 24828436
pmcid: 4020790
Voigt, R. M. et al. Diurnal variations in intestinal barrier integrity and liver pathology in mice: implications for alcohol binge. Am. J. Physiol. Gastrointest. Liver Physiol. 314, G131–G141 (2018).
pubmed: 29074484
Mutlu, E. A. et al. Colonic microbiome is altered in alcoholism. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G966–G978 (2012).
pubmed: 22241860
pmcid: 3362077
Dubinkina, V. B. et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome 5, 141 (2017).
pubmed: 29041989
pmcid: 5645934
Bjarnason, I., Peters, T. J. & Wise, R. J. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1, 179–182 (1984).
pubmed: 6141332
Yang, A. M. et al. Intestinal fungi contribute to development of alcoholic liver disease. J. Clin. Invest. 127, 2829–2841 (2017).
pubmed: 28530644
pmcid: 5490775
Bajaj, J. S. et al. Fungal dysbiosis in cirrhosis. Gut 67, 1146–1154 (2018).
pubmed: 28578302
Albillos, A., de-la-Hera, A. & Alvarez-Mon, M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 363, 1608–1610 (2004).
pubmed: 15145636
Moreau, R. et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J. Hepatol. 72, 688–701 (2020).
pubmed: 31778751
Ridlon, J. M., Alves, J. M., Hylemon, P. B. & Bajaj, J. S. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 4, 382–387 (2013).
pubmed: 23851335
pmcid: 3839982
Kakiyama, G. et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G929–G937 (2014).
pubmed: 24699327
pmcid: 4152166
Verbeke, L. et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am. J. Pathol. 185, 409–419 (2015).
pubmed: 25592258
Ubeda, M. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J. Hepatol. 64, 1049–1057 (2016).
pubmed: 26723896
Sorribas, M. et al. FXR modulates the gut–vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J. Hepatol. 71, 1126–1140 (2019).
pubmed: 31295531
Reiberger, T. et al. Non-selective β-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J. Hepatol. 58, 911–921 (2013).
pubmed: 23262249
Perez-Paramo, M. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31, 43–48 (2000).
pubmed: 10613726
Senzolo, M. et al. β-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 29, 1189–1193 (2009).
pubmed: 19508620
Senzolo, M. et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding? Am. J. Gastroenterol. 104, 3115–3116 (2009).
pubmed: 19956145
Lang, S. et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology https://doi.org/10.1053/j.gastro.2020.07.005 (2020).
Schmidt, T. S. B., Raes, J. & Bork, P. The human gut microbiome: from association to modulation. Cell 172, 1198–1215 (2018).
pubmed: 29522742
Malinchoc, M. et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31, 864–871 (2000).
pubmed: 10733541
Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646–649 (1973).
pubmed: 4541913
Jalan, R. et al. The CLIF consortium acute decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J. Hepatol. 62, 831–840 (2015).
pubmed: 25463539
Such, J. et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 36, 135–141 (2002).
pubmed: 12085357
Alvarez-Silva, C. et al. Compartmentalization of immune response and microbial translocation in decompensated cirrhosis. Front. Immunol. 10, 69 (2019).
pubmed: 30800122
pmcid: 6376951
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).
Yu, J. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 66, 70–78 (2017).
pubmed: 26408641
Chen, Y. et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J. Gastroenterol. Hepatol. 30, 1429–1437 (2015).
pubmed: 25711972
Bajaj, J. S. et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 17, 756–765.e3 (2019).
pubmed: 30036646
Bajaj, J. S. et al. Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. JCI Insight 8, e98019 (2018).
Bajaj, J. S. et al. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. Liver Transpl. 23, 907–914 (2017).
pubmed: 28240840
Bajaj, J. S. et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G675–G685 (2012).
pubmed: 22821944
pmcid: 3468538
Bajaj, J. S. et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 62, 1260–1271 (2015).
pubmed: 25820757
pmcid: 4587995
Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).
pubmed: 29209090
pmcid: 5716994
Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679–689 (2019).
pubmed: 30936547
Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019).
pubmed: 30936548
Pasolli, E. et al. Accessible, curated metagenomic data through ExperimentHub. Nat. Methods 14, 1023–1024 (2017).
pubmed: 29088129
pmcid: 5862039
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
pubmed: 29555994
pmcid: 6108420
Dam, G., Vilstrup, H., Watson, H. & Jepsen, P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 64, 1265–1272 (2016).
pubmed: 27474889
Llorente, C. et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat. Commun. 8, 837 (2017).
pubmed: 29038503
pmcid: 5643518
Bajaj, J. S., Betrapally, N. S. & Gillevet, P. M. Decompensated cirrhosis and microbiome interpretation. Nature 525, E1–E2 (2015).
pubmed: 26381988
pmcid: 4617624
Holte, K., Krag, A. & Gluud, L. L. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol. Res. 42, 1008–1015 (2012).
pubmed: 22548675
Dhiman, R. K. et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147, 1327–1337.e3 (2014).
pubmed: 25450083
Bajaj, J. S. et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 68, 234–247 (2018).
pubmed: 29350768
Sartor, R. B. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment. Pharmacol. Ther. 43, 27–36 (2016).
pubmed: 26618923
Kalambokis, G. N. et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin. Gastroenterol. Hepatol. 10, 815–818 (2012).
pubmed: 22391344
Vlachogiannakos, J. et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J. Gastroenterol. Hepatol. 28, 450–455 (2013).
pubmed: 23216382
Lutz, P. et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS ONE 9, e93909 (2014).
pubmed: 24714550
pmcid: 3979735
Kimer, N. et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial. Hepatology 65, 592–603 (2017).
pubmed: 27775818
Kimer, N. et al. Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis; a randomized trial. J. Gastroenterol. Hepatol. 33, 307–314 (2018).
pubmed: 28671712
Abraldes, J. G. et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150, 1160–1170.e3 (2016).
pubmed: 26774179
Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651–1658 (2009).
pubmed: 19208350
Tripathi, D. M. et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology 155, 1564–1577 (2018).
pubmed: 30055171
Vieira-Silva, S. et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 581, 310–315 (2020).
pubmed: 32433607
Pose, E. et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol. Hepatol. 5, 31–41 (2020).
pubmed: 31607677
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69, 406–460 (2018).
Wiest, R., Krag, A. & Gerbes, A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 61, 297–310 (2012).
pubmed: 22147550
Moreau, R. et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology 155, 1816–1827.e9 (2018).
pubmed: 30144431
Fernandez, J., Tandon, P., Mensa, J. & Garcia-Tsao, G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 63, 2019–2031 (2016).
pubmed: 26528864
Fernandez, J. et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J. Hepatol. 70, 398–411 (2019).
pubmed: 30391380
Piano, S. et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 156, 1368–1380.e10 (2019).
pubmed: 30552895
Cox, L. M. & Blaser, M. J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 11, 182–190 (2015).
pubmed: 25488483
Kerr, R. M., Du Bois, J. J. & Holt, P. R. Use of 125-I- and 51-Cr-labeled albumin for the measurement of gastrointestinal and total albumin catabolism. J. Clin. Invest. 46, 2064–2082 (1967).
pubmed: 5630419
pmcid: 292957
Gortzen, J. et al. Interplay of matrix stiffness and c-SRC in hepatic fibrosis. Front. Physiol. 6, 359 (2015).
pubmed: 26696895
pmcid: 4667086
Klammt, S. et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur. J. Gastroenterol. Hepatol. 19, 257–263 (2007).
pubmed: 17301654
Jalan, R. et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 50, 555–564 (2009).
pubmed: 19642174
Domenicali, M. et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 60, 1851–1860 (2014).
pubmed: 25048618
Bernardi, M., Ricci, C. S. & Zaccherini, G. Role of human albumin in the management of complications of liver cirrhosis. J. Clin. Exp. Hepatol. 4, 302–311 (2014).
pubmed: 25755577
pmcid: 4298636
O’Brien, A. J. et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E
pubmed: 24728410
pmcid: 5369639
Fernandez, J. et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin. Gastroenterol. Hepatol. 18, 963–973.e14 (2020).
pubmed: 31394283
Fernandez, J. et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 157, 149–162 (2019).
pubmed: 30905652
Caraceni, P. et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 391, 2417–2429 (2018).
pubmed: 29861076
Guevara, M. et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J. Hepatol. 57, 759–765 (2012).
pubmed: 22732511
Thevenot, T. et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J. Hepatol. 62, 822–830 (2015).
pubmed: 25463545
Bernardi, M. et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 69, 1127–1138 (2020).
pubmed: 32102926
pmcid: 7282556
Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054–1062.e5 (2017).
pubmed: 28467925
pmcid: 5502730
Bajaj, J. S. et al. Periodontal therapy favorably modulates the oral–gut–hepatic axis in cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 315, G824–G837 (2018).
pubmed: 30118351
pmcid: 6293251
Braham, Y., Meunier, G. & Meunier, B. [Demonstration of an oxidative biotransformation of 9-methoxyellipticine. Comparison with the case of 9-hydroxyellipticine] [French]. C. R. Acad. Sci. III 304, 301–306 (1987).
pubmed: 3103875
Bajaj, J. S. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66, 1727–1738 (2017).
pubmed: 28586116
pmcid: 6102730
Bajaj, J. S. et al. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology 156, 1921–1923.e3 (2019).
pubmed: 30664879
pmcid: 6475479
Bajaj, J. S. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology 70, 1690–1703 (2019).
pubmed: 31038755
pmcid: 6819208
Bajaj, J. S. et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. JCI Insight 4, e133410 (2019).
pmcid: 6975263
DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).
pubmed: 31665575
Hartmann, P., Chu, H., Duan, Y. & Schnabl, B. Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. Am. J. Physiol. Gastrointest. Liver Physiol. 316, G563–G573 (2019).
pubmed: 30767680
pmcid: 6580239
Burroughs, A. K. & Thalheimer, U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology 51, 1894–1896 (2010).
pubmed: 20512984
Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481–488 (2007).
pubmed: 17681169
Trebicka, J., Reiberger, T. & Laleman, W. Gut–liver axis links portal hypertension to acute-on-chronic liver failure. Visc. Med. 34, 270–275 (2018).
pubmed: 30345284
pmcid: 6189544
Cho, E. J. et al. Circulating microbiota-based metagenomic signature for detection of hepatocellular carcinoma. Sci. Rep. 9, 7536 (2019).
pubmed: 31101866
pmcid: 6525191
Ren, Z. et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68, 1014–1023 (2019).
pubmed: 30045880
Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071–1081 (2010).
pubmed: 20335583
Arroyo, V., Claria, J. & Trebicka, J. in Encyclopedia of Gastroenterology 2nd edn (ed. Gerbes, A. L.) 436–443 (Elsevier, 2020).